Pediatric-type follicular lymphoma in a Crohn's disease patient receiving anti-α4ß7-integrin therapy: A case report.
World J Gastroenterol
; 29(43): 5865-5871, 2023 Nov 21.
Article
em En
| MEDLINE
| ID: mdl-38074918
ABSTRACT
BACKGROUND:
Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas (NHL). Vedolizumab (anti-α4ß7-integrin antibody), a treatment-of-choice for Crohn's disease (CD), reduces inflammatory lymphocyte trafficking into the intestinal mucosa. This effect is believed to be confined to the colon. CASESUMMARY:
We report the case of a CD patient on vedolizumab for five years who developed pediatric-type follicular lymphoma. Work-up prior to therapy revealed a reduction in circulating T-lymphocytes and their suppressed response to mitogens. Rituximab, cyclophosphamide, vincristine, and prednisone chemo-immunotherapy resulted in durable lymphoma remission, and vedolizumab treatment was continued. While the patient's T-lymphocyte population and immunoglobulin production recovered, the T-lymphocyte mitogen response remained suppressed.CONCLUSION:
This patient's NHL may be linked to receiving anti-α4ß7 therapy. Further research could be beneficial to determine if proactive surveillance for NHL and other systemic diseases is indicated in patients on vedolizumab.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Crohn
/
Linfoma Folicular
Limite:
Child
/
Humans
Idioma:
En
Revista:
World J Gastroenterol
Ano de publicação:
2023
Tipo de documento:
Article